Skip to main content

Hajdúch Marián M.D., Ph.D.

Journals

SMEŠNÝ TRTKOVÁ, K., P. LUŽNÁ, D. WEISER DROZDKOVA, K. ČÍŽKOVÁ, L. JANOVSKA, J. GURSKÝ, D. PRUKOVA, I. FRYDRYCH, M. HAJDÚCH, J. MINARIK
The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression. Molecular Medicine Reports. 2022, 26(4), 321, ISSN: 1791-2997, PMID: 36043519,
SCHADICH, E., S. NYLEN, S. GURSKÁ, J. KOTULOVÁ, S. ANDRONATI, V. PAVLOVSKY, S. SOBOLEVA, P. POLISHCHUK, M. HAJDÚCH, P. DŽUBÁK
Activity of 1-aryl-4-(naphthalimidoalkyl) piperazine derivatives against Leishmania major and Leishmania mexicana. Parasitology International. 2022, 91, 102647, ISSN: 1383-5769, PMID: 35985636,
KUBÍČKOVÁ, A., Z. MACEČKOVÁ, P. VOJTA, M. ONDRA, J. VOLEJNÍKOVÁ, P. KOŘALKOVÁ, A. JUNGOVA, O. JAHODA, R. MOJZIKOVA, I. HADAČOVÁ, J. CERMAK, M. HORVÁTHOVÁ, D. POSPÍŠILOVÁ, M. HAJDÚCH
Missense mutation in RPS7 causes Diamond-Blackfan anemia via alteration of erythrocyte metabolism, protein translation and induction of ribosomal stress. Blood Cells, Molecules & Diseases. 2022, 97, 102690, ISSN: 1079-9796, PMID: 35871033,

Intellectual property

METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS AND OVERCOMIMG THEIR RESISTANCE (Madhu)
  1. Published Application PCT/CZ2012/000123 under WO 2013/083098 (13.6.2013)
  2. Patent: EP 2788504; Granted: 21.7.2016; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy MadhusudhanHajdúch MariánDžubák PetrSrovnal JosefHrabáková, Kovářová Hana  
  3. Patent: JP 6144696; Granted: 19.5.2017; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy Madhusudhan, Hajdúch MariánDžubák PetrSrovnal Josef, Hrabáková, Kovářová Hana
  4. Patent: CA 2.855.921; Granted: 5.3.2019; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy Madhusudhan, Hajdúch MariánDžubák PetrSrovnal Josef, Hrabáková, Kovářová Hana
  5. Published Application US 2014/0336073 (13.11.2014)

Status: Terminated

DERIVATES OF 2-PHENYL-3-HYDROXYQUINOLINE-4(1H)-ONE AND METHODS OF THEIR PREPARATION AND UTILIZATION (Krejčí)
  1. Patent: CZ 300589; Granted: 13.5.2009; Ownership: Palacky University Olomouc; Inventors: Krejčí Petr, Hlaváč Jan, Hradil Pavel, Hajdúch Marián
  2. Published Application PCT/CZ2007/000075 under WO 2008/028427 (13.3.2008)
  3. Patent: US 8,299,092; Granted: 30.10.2012; Ownership: Palacky University Olomouc; Inventors: Krejčí Petr, Hlaváč Jan, Hradil Pavel, Hajdúch Marián
  4. Patent: EP 2064200; Granted: 4.9.2013; Ownership: Palacky University Olomouc; Inventors: Krejčí Petr, Hlaváč Jan, Hradil Pavel, Hajdúch Marián

Status: Terminated

CAFFEINE-8-HYDRAZONES AS NOVEL CYTOSTATICS FOR THE TREATMENT OF ONCOLOGIC DISEASES (Kaplánek)
  1. Patent: CZ 305625; Granted: 2.12.2015; Ownership: Institute of Chemical Technology Prague, Palacky University Olomouc, Institute of Molecular Genetics CAS; Inventors: Rak Jakub, Kaplánek Robert, Štulcová Tereza, Drašar Pavel, Havlík Martin, Bříza Tomáš, Džubák PetrHajdúch MariánKonečný PetrŠtěpánková Jana, Králová Jarmila, Král Vladimír 

Status: Terminated 

Open positions

Project: Identification of proteomic biomarkers in exhaled air condensate in patients with systemic or pulmonary disease
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: Antitumor drugs targeting nucleic acid metabolism
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: Bioinformatics processing of big data within clinical and preclinical studies
Supervisors: Hajdúch Marián M.D., Ph.D., Pavliš Petr Ph.D.
Available: 3
Intended for: Doctoral training
Summary: 3 places in full-time or combined form of study
Project: Identification of molecular targets and mechanisms of resistance in antitumor drugs using cell biology and proteomics methods
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: Physiology and pathophysiology of aging
Supervisors: Hajdúch Marián M.D., Ph.D., Voller Jiří Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: Drug repurposing for treatment and prevention of diseases
Supervisors: Hajdúch Marián M.D., Ph.D.
Available: 1
Intended for: Doctoral training
Summary: 1 place in full-time study
Project: Drug development of small molecules
Supervisors: Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: Diagnostics and therapy of rare diseases
Supervisors: Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: 2 places in full-time study
Project: New prognostic and predictive factors in solid tumors
Supervisors: Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D.
Available: 3
Intended for: Doctoral training
Summary: 3 places in full-time or combined form of study
Project: Genetic and epigenetic biomarkers of cancer diseases
Supervisors: Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 3
Intended for: Doctoral training
Summary: 3 places in full-time study
Project: Genetic and epigenetic biomarkers in cancer
Supervisors: Drábek Jiří Ph.D., Slavkovský Rastislav Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 3
Intended for: Doctoral training
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) has recently been described as a common phenomenon associated with aging. It is characterized by the accumulation of somatic mutations in cells of the hematopoietic system. Although CHIP is manifested by the expansion of certain cell clones, this condition is not accompanied by any morphological features of hematological neoplasia. However, it has been shown that the incidence of clonal hematopoiesis correlates with increased overall mortality and the risk of developing malignant transformation of hematopoietic cells as well as cardiovascular disease, such as ischemic stroke. To what extent and by what mechanisms clonal hematopoiesis contributes to disease development remains a question of current research. The main aim of the project will be to pinpoint the principal cells carrying CHIP somatic mutations, and to study their role in development and maintenance of atherosclerotic plaques, especially of those involved in development of stroke. The comparison of the phenotype of CHIP positive and negative cells will be of special interest. The use of cellular models not only include different types of leucocytes but circulatory progenitor endothelial cells as well. The study will involve elderly subjects with the positive presence of CHIP (>65 years). Subject will be characterized based on the presence or absence of ischemic stroke and the presence or absence of carotid stenosis by our clinical collaborators. The presence of somatic variants in 38 selected genes associated with CHIP will be tested in subjects of interest within our research group. The project will use various techiques including FACS, MACS, cell cultures, DNA isolation from small amount of cells, a highly sensitive sequencing method for DNA genotyping allowing detection of variant with less than 1% allelic frequency, DNA/RNA sequencing library preparation, deep massively parallel sequencing of panel of genes using unique molecular barcodes/indices, RNAseq, bioinformatics and data analysis with possibilities of calculations using high performance computing cluster, data management and statistical evaluation.
Project: Identification of proteomic biomarkers in exhaled breath condensate in patients with systemic or pulmonary disease
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: Ph.D. topic is focused on the identification of biomarkers of lung diseases by means of a non-invasive collection of exhaled breath condensate. The project will monitor the presence of proteins in exhaled air in various diseases such as asthma, cystic fibrosis, lung tumors, or some infectious diseases, as well as quantitative changes of these proteins compared to a healthy population. Changes in these potential biomarkers with respect to therapeutic response and disease progression will be evaluated and validated.
Project: Identification of novel proteomic cancer biomarkers
Supervisors: Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: New prognostic and predictive factors in solid tumors
Supervisors: Srovnal Josef M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: Cancer is the second leading cause of death in the western countries. Early diagnosis and targeted therapy improve the therapeutic outcome. With the emergence of new biotechnologies, diagnosis can be made early and precisely, and the knowledge of tumor molecular genetics can identify the most appropriate therapy for a particular patient. The sensitivity of modern molecular methods makes it possible to characterize the tumor properties from sites remote from the primary tumor using patient's blood. The subject of the offered study program is the identification of new prognostic and predictive biomarkers of cancer using liquid biopsies. This is particularly the analysis of circulating tumor cells (CTCs), circulating free tumor DNA (ctDNA) and circulating miRNAs. The aim of the project is to further implement a liquid biopsy concept into the diagnosis and therapy monitoring of solid tumors, especially colorectal, breast, lung and CNS tumors. These include therapy response and resistance monitoring, identifying new therapeutic targets and estimating disease prognosis. The project will provide training in widely-used, transferable techniques, including circulation tumor cells capture system, digital droplet PCR, reverse-transcription qPCR, RNA-seq, single cell analyses, xenografts models and other multi-omics methods. We are looking for candidates with a background in Molecular Biology, Medicine, Cell Biology or a related area, who are enthusiastic about investigating novel approaches in cancer diagnostic that have significant potential for public health.
Project: Pharmacokinetic methods in preclinical drug testing
Supervisors: Hajdúch Marián M.D., Ph.D., Lišková Barbora Ph.D.
Available: 1
Intended for: Doctoral training
Summary: The study of ADME properties of a potential drug that are part of the IMTM chemical library - obtained by national or international cooperation belongs to one of the first steps in predicting potential drugs. In vitro models generate many ADME parameters, including chemical, plasma and microsomal stability, plasma protein binding and proportion of passive diffusion as a transport mechanism. The Caco-2 and MDCK-MDR1 permeability assays are established models of intestinal and blood-brain barriers, respectively. Analysis of samples is performed using a Agilent RapidFire 300 - rapid online solid phase extraction with subsequent detection of the mass spectrometer Qtrap 5500 (AB Sciex) - RF/MS. High-Throughput Mass Spectrometry System RF/MS delivers ultrafast, label – free analysis of native compounds for biochemical assays in ADME and provide throughput speeds of 6 to 10 seconds per sample.
Project: Identification of molecular targets of anticancer therapy applying cell biology and proteomics tools
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: Selected, highly active derivatives of triterpenes, chelators and nucleosides will be studied with a view to identify the mechanisms of their antitumor effects. Advanced methods of cell biology, proteomics and genomics such as affinity purification of protein targets, CETSA and others will be used for their study. The identified targets will be validated in relation to their clinical relevance in anticancer therapy.
Project: Drug resistance mechanisms in cancer
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: Mechanisms of tumor cell resistance to newly developed and existing nucleoside analog cytostatics will be studied. These drugs are used in most anti-cancer therapy protocols and the emergence of drug resistance is a major problem in the treatment of cancer patients. Resistant cell lines prepared in the past will be studied to identify the key mechanisms of resistance, which will be carried out by their detailed characterization using cell biology, but also proteomics and molecular genetics. The significance of the identified changes will be further verified on clinical material and will be applied in the development of new anticancer drugs from this class.
Project: Biology of aging and DNA damage
Supervisors: Hajdúch Marián M.D., Ph.D.
Available: 1
Intended for: Doctoral training
Project: Pathological conditions associated with human papillomavirus infection
Supervisors: Koudeláková Vladimíra Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Summary: High-risk human papillomavirus infection (HPV infection) is associated with several cancers such as cervical, vaginal, vulvar, head and neck, anal, and penile carcinomas. Nearly all cervical cancers are caused by HPV infection. Despite available vaccination and cervical cancer screening program, cervical cancer is one of the most common types of cancer affecting women worldwide. Main problems of cervical cancer screening are low participation rate and low sensitivity of cytology which is still used in the majority of cervical cancer screening programs. Solution could be the transition to primary HPV screening and the sending of self-sampling devices to cervical cancer screening non-attenders. The best strategy for enrolling Czech women in the screening program will be analysed during this project. Obtained samples will be tested for the presence of HPV DNA and the presence of other molecular biomarkers important in viral clearance and cervical cancer progression/regression. Discoveries will lead to identification of biomarkers for early diagnosis, disease progression or triage strategies. The aim of the project is to clarify the best strategy for enrolling women who do not attend cervical cancer screening program. The second aim is to study genetic and proteomic profile of HPV positive/negative women with normal/abnormal cervical cytology as well as genetic variants of HPV and its importance for regression/progression of the disease. Skills to be taught include biochemistry, molecular biology, bioinformatics and cell culture. This is an ideal project for a student who wishes to pursue higher studies in cancer research. The project will use various techniques including PCR, in situ hybridization, next generation sequencing, mass spectrometry.
Project: Identification of molecular targets and resistance mechanisms of anticancer drugs by cell biology and proteomics methods
Supervisors: Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Identification of proteomic biomarkers in exhaled breath condensate patients with systemic or pulmonary disease
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Bioinformatics processing of big data in clinical and preclinical studies
Supervisors: Hajdúch Marián M.D., Ph.D., Pavliš Petr Ph.D., Vrbková Jana Ph.D.
Available: 3
Intended for: Doctoral training
Project: Drug repurposing for treatment and prevention of diseases
Supervisors: Hajdúch Marián M.D., Ph.D., Gurská Soňa Ph.D.
Available: 2
Intended for: Doctoral training
Project: Biologically active molecules and their therapeutic combinations
Supervisors: Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Anticancer drugs targeting nucleic acid metabolism
Supervisors: Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Synthesis and characterization of 2D nanoplatforms as active drug carriers
Supervisors: Ranc Václav Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 3
Intended for: Doctoral training
Project: Physiology and pathophysiology of ageing
Supervisors: Hajdúch Marián M.D., Ph.D., Voller Jiří Ph.D.
Available: 2
Intended for: Doctoral training
Project: Identification of proteomic biomarkers in proximal fluids and tissues
Supervisors: Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Diagnosis and treatment of rare diseases
Supervisors: Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: New methods in protein degradation
Supervisors: Holub Dušan Ph.D., Hajdúch Marián M.D., Ph.D.
Available: 2
Intended for: Doctoral training
Project: Research and development of agents for cancer, neurodegenerative and infectious diseases
Supervisors: De Sanctis Juan Bautista Ph.D., Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D., Urban Milan Ph.D., Das Viswanath M.Sc., Ph.D.
Available: 5
Intended for: Doctoral training
Project: New prognostic and predictive factors in solid tumors
Supervisors: Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D., Koudeláková Vladimíra Ph.D.
Available: 3
Intended for: Doctoral training
Project: Genetic and epigenetic biomarkers in health and disease
Supervisors: Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D., Drábek Jiří Ph.D., Koudeláková Vladimíra Ph.D.
Available: 5
Intended for: Doctoral training